MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
headlines news headlines   email email to a friend   printer printer friendly   newsletter sign up to newsletter  

Grand Opportunity Grant Funds Rapid Saliva Test Using Lab-On-A-Chip

Main Category: Cancer / Oncology
Also Included In: Dentistry | Medical Devices / Diagnostics | IT / Internet / E-mail
Article Date: 07 Nov 2009

The National Institutes of Health (NIH) has awarded researchers in Rice University's new BioScience Research Collaborative (BRC) a $2 million Grand Opportunity (GO) grant to develop a fast, inexpensive test for oral cancer that a dentist could perform simply by using a brush to collect a small sample of cells from a patient's mouth.

"We want to provide an accurate diagnosis for oral cancer in less than 30 minutes using a minimally invasive test that requires no scalpels or off-site lab tests," said principal investigator John McDevitt, Rice's Brown-Wiess Professor in Bioengineering and Chemistry. "The payoff for this could be tremendous because oral cancers today are typically diagnosed much too late in their development."

NIH established the GO grant program to support projects that address large, specific research endeavors that are likely to deliver near-term growth and investment in biomedical research and development, public health and health care delivery. GO grant funding was provided by the American Recovery and Reinvestment Act.

If oral cancer is detected early, the prognosis for patients is excellent, with a five-year survival rate of more than 90 percent. Unfortunately, the actual five-year survival rate for oral squamous cell carcinoma is only about 50 percent, among the lowest rates for all major cancers. Oral squamous cell carcinoma affects about 300,000 people per year worldwide, and most cases are diagnosed in their late stages.

The new test is possible because of a novel microchip invented in McDevitt's lab. This "lab-on-a-chip" uses the latest techniques in microchip design, nanotechnology, microfluidics, image analysis, pattern recognition and biotechnology to shrink many of the main functions of a state-of-the-art clinical pathology laboratory onto a microchip the size of a postage stamp.

The microchips are mounted on disposable, plastic cards that are slotted into a battery-powered analyzer. A brush-biopsy sample is placed on the card and microfluidic circuits wash cells from the sample into a reaction chamber. The cells pass through mini-fluidic channels about the size of small veins and come in contact with "biomarkers" that react only with specific types of diseased cells. The machine uses two LEDs, or light-emitting diodes, to light up various regions of the cells and cell compartments. Healthy and diseased cells can be distinguished from one another by the way they glow in response to the LEDs.

The oral-cancer test will be developed in collaboration with scientists at the University of Texas M.D. Anderson Cancer Center, the University of Texas Health Science Center at Houston, the University of Texas Health Science Center at San Antonio and the University of Sheffield in the United Kingdom. In addition to cancer, McDevitt's lab is developing tests for heart attacks and HIV, and it is developing a process to produce the disposable cards for pennies apiece.

"An affordable oral-cancer test that can be performed painlessly and quickly in either a regular visit at the doctor or dentist's office benefits patients and clinicians by detecting cancer earlier and lowering health care costs," McDevitt said.

The analyzers used in the test are made by Austin-based startup LabNow, a company McDevitt launched while at the University of Texas at Austin. McDevitt moved his lab from UT-Austin to Rice in July 2009 to be in the BRC, a state-of-the-art research facility that's within walking distance of the major research institutions of the Texas Medical Center (TMC). McDevitt's lab is slated to begin trials of a lab-on-a-chip saliva test for heart attacks with the TMC's Baylor College of Medicine in January. In addition, LabNow is preparing for tests next spring in Africa of a lab-on-a-chip test for HIV immune function.

Source: Jade Boyd
Rice University

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.





For any corrections of factual information, or to contact the editors please use our feedback form.
Send your press releases to








free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.